Phio Pharmaceuticals ROE 2024

Phio Pharmaceuticals Aktienanalyse

What does Phio Pharmaceuticals do?

Phio Pharmaceuticals Corp is a biopharmaceutical company focused on developing therapeutic products for the treatment of cancer and infectious diseases. The company is headquartered in Marlborough, Massachusetts and was founded in 1995. Phio Pharmaceuticals Corp. (formerly RXi Pharmaceuticals Corporation) originated in Worcester, Massachusetts, when founders Craig Mello and other researchers at the University of Massachusetts Medical School discovered how RNA interference (RNAi) could be used to combat diseases. The RNAi technology aims to manipulate the DNA code in cells to block the production of proteins related to disease. This technology has the potential to revolutionize the therapeutic landscape by enabling faster, more efficient, and more precise treatments than previous approaches. Phio has developed unique technologies to selectively deliver RNAi molecules to cancer tissue. The technology utilizes a family of compounds called "self-delivering RNA" (sd-rxRNA). These molecules are capable of targeting cancer cells and destroying them from within without affecting healthy cells. Phio believes that its technology has the potential for broad applications in cancer therapy and aims to treat a variety of cancer types. Phio has also developed a technology platform called "immunostimulatory RNA" (isRNA) that aims to activate the body's immune system to recognize and attack cancer cells. When injected into cancer cells, isRNA molecules can cause the immune system to recognize and attack the cancer cells as foreign. This technology has the potential to create a new class of immunotherapeutics that combines the benefits of RNAi and immunotherapy. Phio also has products in the development phase for the treatment of infectious diseases. It has developed an siRNA program for the inhibition of hepatitis B and is currently working on the development of therapeutics against dengue fever and the Zika virus. Phio has a partnership with the Karolinska Institutet, a world-leading medical university in Stockholm, Sweden, to further develop its sd-rxRNA technology. The collaboration aims to confirm the efficacy and safety of the technology and explore potential new applications in cancer therapy and other disease areas. Phio considers its sd-rxRNA products as a potentially disruptive technology that can reduce the need for conventional chemotherapy and radiation therapies, which can have high toxicity and severe side effects in many patients. The technology has the potential to create effective therapies with minimal side effects. Overall, Phio is an emerging company with a promising technology platform that has the potential to fundamentally change the therapeutic landscape. The partnership with a leading medical university and the comprehensive development pipeline suggest that the company is on track to conduct clinical trials in the near future and possibly achieve successful market launches. Phio Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding Phio Pharmaceuticals's Return on Equity (ROE)

Phio Pharmaceuticals's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Phio Pharmaceuticals's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Phio Pharmaceuticals's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Phio Pharmaceuticals’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Phio Pharmaceuticals Stock

What is the ROE (Return on Equity) of Phio Pharmaceuticals this year?

The ROE of Phio Pharmaceuticals this year is -1.4 undefined.

How has the Return on Equity (ROE) of Phio Pharmaceuticals developed compared to the previous year?

The ROE of Phio Pharmaceuticals has increased by 32.24% increased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of Phio Pharmaceuticals?

A high ROE indicates that Phio Pharmaceuticals generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of Phio Pharmaceuticals?

A low ROE can indicate that Phio Pharmaceuticals is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of Phio Pharmaceuticals affect the company?

A change in ROE (Return on Equity) of Phio Pharmaceuticals can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of Phio Pharmaceuticals?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of Phio Pharmaceuticals?

Some factors that can influence Phio Pharmaceuticals's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does Phio Pharmaceuticals pay?

Over the past 12 months, Phio Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Phio Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Phio Pharmaceuticals?

The current dividend yield of Phio Pharmaceuticals is .

When does Phio Pharmaceuticals pay dividends?

Phio Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Phio Pharmaceuticals?

Phio Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Phio Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Phio Pharmaceuticals located?

Phio Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Phio Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Phio Pharmaceuticals from 5/16/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 5/16/2024.

When did Phio Pharmaceuticals pay the last dividend?

The last dividend was paid out on 5/16/2024.

What was the dividend of Phio Pharmaceuticals in the year 2023?

In the year 2023, Phio Pharmaceuticals distributed 0 USD as dividends.

In which currency does Phio Pharmaceuticals pay out the dividend?

The dividends of Phio Pharmaceuticals are distributed in USD.